LOWELL, Mass., Oct 24 (Bernama-GLOBE NEWSWIRE) -- Rapid
Micro Biosystems, a leading provider of automated, non-destructive,
rapid microbial detection, is pleased to announce the receipt of a $7.3
million contract from the Biomedical Advanced Research and Development
Authority (BARDA) for the implementation of a rapid sterility test for
vaccines. This awarded grant is part of BARDA’s Advance Development of
Medical Countermeasures for Pandemic Influenza, which focuses on
improving the government’s responsiveness to future pandemic threats.
When combined with Rapid Micro Biosystems’ automated Growth Direct™
detection system, the rapid sterility test will result in faster release
of vaccines and other sterile products. Timely delivery of these
products carries multiple public benefits, principally in facilitating
rapid responses to pandemic or emerging infections, agents of
bioterrorism, and availability of life saving medicines.
“Our
continuing relationship with BARDA demonstrates the critical need for
rapid sterility testing as part of our response to immediate health
threats,” said Robert Spignesi, Chief Executive Officer at Rapid Micro
Biosystems.
“Our unique detection technology will show
contamination within hours and will provide results in half the time of
the traditional 14-day test,” said Edward Ognibene, Vice President
Development at Rapid Micro Biosystems.
The team at Rapid Micro
Biosystems has extensive experience in product development,
manufacturing, and service of rapid microbial quality control products,
and has previously worked successfully with BARDA to develop the
fundamental technology for a rapid sterility test. Upon completion of
the program, the resulting product will make valuable improvements to
the quality control release of sterile vaccines and other lifesaving
pharmaceutical products and will immediately benefit the public.
About Rapid Micro Biosystems
Rapid
Micro Biosystems creates innovative products for fast, accurate, and
efficient detection of microbial contamination in the manufacture of
pharmaceuticals, biologics, medical devices, and personal care products.
The company’s Growth Direct™ System is the first and only
non-destructive, growth-based system to automate microbial quality
control testing. By automating and accelerating the detection and
enumeration of environmental monitoring, bioburden and sterility
testing, the Growth Direct decreases QC testing time, ensures data
integrity, and reduces the risk of costly contamination events. For more
information about Rapid Micro Biosystems visit www.rapidmicrobio.com
Contact:
Eugenia Kendrick
Rapid Micro Biosystems
ekendrick@rapidmicrobio.com
SOURCE : Rapid Micro Biosystems
No comments:
Post a Comment